GRAL — GRAIL, Inc.

Nasdaq · Health Care · Health Care Providers & Services · CIK 1699031 ·
Last close
$59.81
Market Cap
$2.57B
52W High
$79.50
52W Low
$44.06
ADV30
788,002
Next earnings
2026-05-05
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 40,785,000 -14,307,000 -135,765,000 -93,187,000 2,803,474,000 69,344,000 302,788,000
Dec 2025 43,597,000 -11,136,000 -124,411,000 -99,176,000 2,922,015,000 249,727,000 344,153,000
Sep 2025 36,194,000 -13,733,000 -125,291,000 -88,977,000 2,601,031,000 126,892,000 361,068,000
Jun 2025 35,544,000 -17,775,000 -130,854,000 -113,985,000 2,702,551,000 127,427,000 387,908,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-290,984,000
Investing CF
$-193,098,000
Financing CF
$423,321,000
CapEx
$-1,350,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-10.37
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-10,304,868,000
Inventory
$17,194,000
Receivables
$20,345,000
ST Investments
$753,761,000
EBIT TTM
$-516,321,000
Pretax Income TTM
$-515,615,000
Interest Exp TTM
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$156,120,000
EBITDA
$-360,496,000
Free Cash Flow
$-107,751,872
Enterprise Value
$1,794,766,464
Total Cash
$823,105,024
Total Debt
$51,030,000
Shares Out
42,916,593
Trailing EPS
$-10.30
Book Value
$60.79
ROE
-16.1%
ROA
-11.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 147,172,000 -534,163,000 -408,351,000 2,922,015,000 344,153,000 -299,007,000
Dec 2024 125,595,000 -768,222,000 -2,027,005,000 2,983,307,000 479,902,000 -577,156,000
Dec 2023 93,105,000 -796,916,000 -1,465,685,000 3,913,814,000 267,627,000 -595,800,000
Dec 2022 55,550,000 -742,459,000 -5,399,098,000 4,937,986,000 291,825,000 -561,313,000

TTM Snapshot

Revenues TTM
$28,652,000
NetIncome TTM
$-125,688,000
OpCashFlow TTM
$0
Assets (Latest)
$2,983,307,000
Forward EPS
$-9.72

Max Pain — expiry 2026-06-18

max pain strike: $60.00 · spot: $58.29 · call oi: 3,654 · put oi: 1,909
Expected Move to 2026-06-18: ±$3.65 (6.26%) — implied range $54.64$61.94 · ATM straddle on $60.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ACHC Acadia Healthcare Company, Inc. $2.30B $24.99
PRVA Privia Health Group, Inc. $2.90B $23.02
NHC NATIONAL HEALTHCARE CORP $3.06B $195.59
PGNY Progyny, Inc. $2.11B $26.91
SEM SELECT MEDICAL HOLDINGS CORP $2.06B $16.65

News headlines (Yahoo Finance, 1h cache)

Honeywell Stock Is Likely to Reward Shareholders Following Quantinuum IPO, Split
2026-06-04 13:35 · Yahoo
A Look At GRAIL (GRAL) Valuation After A Sharp One Day Share Price Drop
2026-06-02 21:18 · Yahoo
Grail Plummets On Mixed Results For Cancer-Screening Blood Test
2026-06-01 20:32 · Yahoo
GRAIL (GRAL) Is Up 6.7% After Mixed Galleri Trial Data At ASCO 2026 - Has The Bull Case Changed?
2026-06-01 17:12 · Yahoo
GRAIL, Inc. (GRAL): One of the Best Stock Picks of Jeff Bezos
2026-06-01 17:11 · Yahoo
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as AI Optimism Overshadows Middle East Risks
2026-06-01 13:03 · Yahoo
GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint
2026-06-01 01:03 · Yahoo
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual
2026-05-31 12:00 · Yahoo
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
2026-05-30 12:00 · Yahoo
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-05-27 20:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.